Testing for measurable (or minimal) residual disease (MRD) can be a powerful tool in shaping treatment plans and overall patient management to achieve better outcomes. MRD refers to the presence of residual microscopic cancer cells detected after cancer treatment which may have been missed by more conventional scans or tests. Unfortunately, routine MRD testing is variable, and there are currently no standards for optimal MRD testing. To address this disparity, ACCC has established an educational project to create helpful tools and recommend effective practices that multidisciplinary providers can use to successfully integrate MRD testing into their cancer care continuum—specifically for patients with B-cell acute lymphoblastic leukemia (ALL).
The project provides valuable information and guidance to members of multidisciplinary cancer care teams, including pathologists, oncologists, advanced practice providers, pharmacists, social workers, financial advocates, administrators, IT professionals, policy analysts, and other relevant specialists.
As B-cell ALL was the first disease state with an FDA-approved treatment for MRD, this project helps lay the foundation for MRD testing in patients with B-cell ALL with an innovative Implementation Roadmap, inclusive of a comprehensive self-assessment tool.
Ultimately, this work showcases not only the importance of MRD testing, but also how it can be best integrated into the cancer care workflow.
Specifically, this project:
For more information on this project, please contact the ACCC Provider Education department.
Measurable residual disease (MRD) testing for patients with acute lymphoblastic leukemia is a powerful prognostic tool, playing an important role in the determination of treatment. ACCC provides useful resources to assist in the successful integration of MRD testing into the cancer care continuum for patients. This resource highlights the value of MRD testing; available tools and resources for MRD testing program implementation; as well as Inova Schar Cancer Institute and Northwell Health Cancer Institute's experiences and assessment of ACCC’s Measurable Residual Disease Testing Implementation Roadmap.
Learn about the basics of MRD testing and how to assess your program’s buy-in to implement or expand MRD testing.
Learn how clinical and non-clinical staff are involved in MRD testing, how to assess your program’s communication and staffing needs, and how to develop an implementation plan.
Learn how to assess your clinical workflow needs to implement MRD testing and how to evaluate, pilot, and refine MRD testing in your program.
Gain important and practical information for the assessment of measurable residual disease as part of routine clinical practice for patients with chronic lymphocytic leukemia (CLL).
MRD Testing Implementation Roadmap
Navigate how to lay the groundwork for MRD testing, prepare your care team, implement testing, and evaluate ongoing progress.
MRD Testing Resource Library
Curated materials to help establish and implement MRD testing for your patients with adult B-cell ALL.